Anne Wilhøft Kristensen

Anne Wilhøft Kristensen

Auto-generated profile, based on publicly available information

Anne Wilhøft Kristensen

Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2022 in Research Involvement and Engagement
Verified
Journal Article
Open access
PDF file
JFJeanette Finderup
Jeanette Finderup
LBLouise Engelbrecht Buur
Louise Engelbrecht Buur
STSarah Cecilie Tscherning
Sarah Cecilie Tscherning
AJAnnesofie Lunde Jensen
Annesofie Lunde Jensen
AKAnne Wilhøft Kristensen
Anne Wilhøft Kristensen
LRLotte Ørneborg Rodkjær
Lotte Ørneborg Rodkjær
Background: Although interest in Patient and Public Involvement in health-related research is growing, there seems to be a lack of guidance supporting researchers in deciding on methods and levels for Patient and Public Involvement in health-related research throughout the research process. Furthermore, the numerous definitions, methods, and frameworks make it challenging for researchers new to this field to decide on the most appropriate approach for their project. Methods: This study aimed to develop and test guidance for researchers deciding on approaches, levels, and methods for engaging patient partners in health-related research. A group of 11 researchers in Patient and Public Involvement in health-related research participated in six workshops to develop the guidance. The feasibility and acceptability of the guidance were tested in a survey of 14 researchers using the System Usability Scale plus two elaborative questions. The guidance was also tested by five PhD students engaging patient partners in their projects. Results: The guidance developed consisted of two resources: Resource I outlined five international approaches to Patient and Public Involvement in health-related research, and Resource II described the different levels and methods for engaging patient partners in research. The System Usability Scale score (at the 50th percentile) was 80, indicating excellent usability. Qualitative data showed that the two resources supported reflections regarding different approaches, levels, and methods. Conclusion: The researchers found the guidance to be supportive of their reflective thinking about engaging patient partners in their research. The testing provided knowledge about when and how to use the guidance but also raised questions about the usefulness of the guidance in communications with patients.

7 December 2023 in Research Involvement and Engagement
Verified
Journal Article
Open access
PDF file
MCMille Guldager Christiansen
Mille Guldager Christiansen
HPHelle Pappot
Helle Pappot
CHClayon Hamilton
Clayon Hamilton
TLTrine Lund-Jacobsen
Trine Lund-Jacobsen
AKAnne Wilhøft Kristensen
Anne Wilhøft Kristensen
KPKarin Piil
Karin Piil
Background: Patient and Public Involvement (PPI) in health research is gaining increased attention and acceptance worldwide. Reliable measurements are crucial to accurately assess, monitor, and evaluate patient involvement efforts in research. The Patient Engagement in Research Scale (PEIRS-22) measures meaningful patient and family caregiver engagement in research. This study focuses on three primary objectives: (1) translation of the PEIRS-22 from English to Danish, followed by linguistic validation and cultural adaptation; (2) assessing the applicability of the Danish PEIRS-22; and (3) focus group interviews to explore the user experiences of PPI. Methods: A three-phase multi-method study was conducted. In phase one, the PEIRS-22 was translated, linguistically validated and culturally adapted to Danish. In phase two individuals from three distinct patient cancer advisory boards responded to the Danish version of PEIRS-22 to assess its applicability. Three focus group interviews were conducted in phase three, involving individuals from three patient cancer advisory boards. Results: The translation process resulted in a Danish version of PEIRS-22, conceptually and culturally equivalent to the English version. Overall, among individuals of the three advisory boards (n = 15) the applicability was found to be satisfactory, with no missing data and all items completed. The total PEIRS-22 score among the three advisory boards was 85.2 out of a possible 100, with higher scores indicating greater meaningful involvement. A nested sample of the three patient cancer advisory boards (n = 9) participated in focus group interviews. The analysis yielded four themes: (1) The Danish PEIRS-22 captured the intended cultural meaning and contributed to self-reflection, (2) Internal motivation is a driver for involvement (3), Involvement brought a personal sense of empowerment and (4) Meaningful involvement collaborations are fostered by a trustful atmosphere. Conclusions: The PEIRS-22 questionnaire has been translated, linguistically validated, and culturally adapted into Danish. We propose that the PEIRS-22 is now ready for use in Danish populations. This study provides a Danish version of the questionnaire that can be used to develop patient-centred practices and foster meaningful involvement and collaborations between patients and researchers in the field of cancer research in Denmark. Personal benefits of participating in PPI can vary, and we recommend using PEIRS-22 in conjunction with a qualitative approach to better explore perspectives on meaningful involvement. Trial registration: The study was registered prospectively on October 22, 2022, by the Danish Data Protection Agency (jr. nr. P-2022–528).

13 December 2023 in Technical Innovations & Patient Support in Radiation Oncology
Verified
Journal Article
Open access
AKAnne Wilhøft Kristensen
Anne Wilhøft Kristensen
AJAnnesofie Lunde Jensen
Annesofie Lunde Jensen
KJKenneth Jensen
Kenneth Jensen
SDSusanne Oksbjerg Dalton
Susanne Oksbjerg Dalton
JFJeppe Friborg
Jeppe Friborg
CGCai Grau
Cai Grau
Clinical trials lead the progress in healthcare. To ensure reliable research conclusions, it is essential to enroll diverse patient groups. Identifying and understanding patient-reported barriers to clinical trials may help enhance recruitment among diverse patient groups. The clinical potential of proton therapy (PT) to reduce late effects is being investigated in clinical trials worldwide. Thus, for some patients, PT is only accessible by participating in clinical trials. Individuals with smoking-related head and neck cancer (HNC) are sometimes socioeconomically deprived, leading to barriers to trial participation. This study aims to identify barriers to their participation in a randomised controlled trial (RCT) involving PT. Interviews were conducted with 14 HNC patients declining participation in an RCT involving PT. The interviews were transcribed and systematically analysed using an inductive approach identifying categories and themes. The identified barriers to RCT-participation are: (1) existential distress, which influenced participants' mental and cognitive capacities, (2) insufficient RCT-related knowledge arising from information overload during clinical consultations, (3) the wish for safety and familiarity during the treatment trajectory, particularly for participants needing accommodation during radiotherapy, and (4) the motivation for study participation was impacted by uncertainty due to randomisation and clinical equipoise. Existential distress is identified as an overarching theme because it influences and amplifies the other three themes. Existential distress is a central theme that influences and amplifies other participation barriers in PT RCTs. It affects participants' comprehension of trial information, their preference for familiar environments, and their motivation to participate in clinical trials.

10 July 2025 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
AKAnne Wilhøft Kristensen
Anne Wilhøft Kristensen
KJKenneth Jensen
Kenneth Jensen
AJAnnesofie L. Jensen
Annesofie L. Jensen
SDSusanne Oksbjerg Dalton
Susanne Oksbjerg Dalton
JEJesper Eriksen
Jesper Eriksen
CGCai Grau
Cai Grau
Background and purpose: Participation in proton therapy (PT) trials may be affected by structural, clinical, and individual factors, potentially excluding certain patient groups. Such disparities can lead to unequal access to potential research benefits and may limit the generalisability of trial findings. This study aimed to identify factors associated with participation in a Danish randomised controlled trial (RCT) comparing proton versus photon radiotherapy for head and neck cancer. Patients and methods: This national cross-sectional study invited patients with pharyngeal and laryngeal cancer, referred for curative-intent radiotherapy at seven Danish radiotherapy clinics between 2022 and 2025, to complete a survey. Respondents were categorised based on enrollment status in a national RCT comparing proton versus photon radiotherapy. Clinical, demographic, psychosocial, and lifestyle data were collected and linked to clinical registry data. Multiple logistic regression was used to assess exposure variables associated with trial participation. Results: Of 304 respondents, 120 (39%) were enrolled in the RCT. Female gender, older age, greater geographical distance to the PT centre, mobility limitations, lower self-rated health status, and lower ability to actively engage with healthcare providers (Health Literacy Questionnaire scale 6) were significantly associated with lower odds of participation. No significant associations were observed for income, education, marital status, or anxiety. Interpretation: The findings indicate that demographic, geographical, functional, and communication-­related factors may limit participation in PT trials. This highlights the need for interventions that enhance the delivery of trial information, strengthen communication between patients and healthcare professionals, and support informed clinical trial decision-making.

28 June 2024 in Technical Innovations & Patient Support in Radiation Oncology
Verified
Journal Article
Open access
AKAnne Wilhøft Kristensen
Anne Wilhøft Kristensen
CGCai Grau
Cai Grau
KJKenneth Jensen
Kenneth Jensen
SDSusanne Oksbjerg Dalton
Susanne Oksbjerg Dalton
JFJeppe Friborg
Jeppe Friborg
AJAnnesofie Lunde Jensen
Annesofie Lunde Jensen
Physicians manage multiple obligations, providing best-practice treatment and patient- centred care in the standard treatment pathway while contributing to clinical trials simultaneously. These multifaceted responsibilities may introduce barriers and dilemmas to clinical trial execution, potentially impacting the clinical trial decision- making process. This study explores physicians’ barriers and dilemmas in executing clinical trials and the impact on clinical trial decision-making. Qualitative semi-structured interviews were conducted with experienced oncologists. Moreover, participant observations were performed during clinical encounters involving discussions about clinical trials. The analysis followed a structured approach: (1) transcription of data, (2) inductive text coding, (3) exploration of patterns, and (4) interpretation, leading to the results. The results were discussed and validated by the study participants. The results comprise (1) a description of the clinical practice, which presents the setting of clinical trial execution; (2) results regarding physicians’ barriers and dilemmas in executing clinical trials, leading to (3) the impact on clinical trial decision- making. The results involve barriers to time constraints for clinical trial tasks, dilemmas emerging from trial requirements or deviations from standard guidelines, and challenges with providing sufficient trial communication and adequate decision-making support, balancing between a paternalistic approach and respecting patient autonomy. The demanding obligations of clinical practice constitute a complex setting for executing clinical trials, resulting in numerous barriers and dilemmas that impact the decision-making process in clinical trials. The study emphasises the need for tailored clinical trial decision-making interventions to facilitate supportive, informed, and non-directive clinical trial decision-making.

15 November 2024 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
JFJeanette Finderup
Jeanette Finderup
HBHilary L. Bekker
Hilary L. Bekker
NANadia Thielke Albèr
Nadia Thielke Albèr
SBSusanne Boel
Susanne Boel
LBLouise Engelbrecht Buur
Louise Engelbrecht Buur
AGAnik Giguère
Anik Giguère
Shared decision making in healthcare is a fundamental right for patients. Healthcare professionals' perception of their own abilities to enable shared decision making is crucial for implementing shared decision making within service. IcanSDM (I can shared decision making) is a brief measure to investigate healthcare professionals' perception of shared decision making approaches to their practices. It was developed in Canada with French and English versions, and recently translated into German. This study aims to adapt the IcanSDM measure for Danish-speaking healthcare professionals, and evaluate its psychometric properties. Cultural adaptation and translation based on Beaton et al.'s approach was applied. A forward translation by ten people and a backward translation by two people were performed. To assess comprehensibility, cognitive interviews were conducted with 24 healthcare professionals. Eighty healthcare professionals who were trained in shared decision making for either one hour (n = 65) or one day (n = 15) participated in the psychometric evaluation. The evaluation concerned acceptance, item characteristics, skewness, item difficulties, corrected item-total correlations, inter-item correlations, factorial structure, internal consistency, and responsiveness. The forward and backward translation revealed few discrepancies, and participants understood the items well. The psychometric evaluation showed a high completion rate and acceptable item difficulties and discrimination values. Both the factor analysis and the internal consistency showed a 2-factor structure: 1) healthcare professionals' capacity to implement shared decision making; and 2) healthcare professionals' capacity to practise shared decision making. The IcanSDM_Danish obtained a Cronbach’s alpha coefficient of 0.74. The evaluation of responsiveness showed improvement, but was not statistically significant. The IcanSDM_Danish has good cross-cultural validity and internal consistency, and a 2-factor structure. The IcanSDM_Danish is capable of providing reliable and valid measurement when evaluating constructed knowledge about shared decision making, and may be able to support the implementation of shared decision making training and evaluation of its impact.